Cellect Biotechnology Reports First ApoGraft Bone Marrow Transplantation in First Patient in United States
Sep 3, 2021 By MarketDepth
Cellect Biotechnology Ltd. (NASDAQ: APOP) reported the first ApoGraft transplantation in a Leukemia patient in the company’s clinical trial at Washington University. ApoGraft is a product based on the company’s cell selection technology that has been designed to optimize immune therapy. After the close of the previous announced merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraft development will be pursued by EnCellX, the company acquiring Cellect’s proprietary technology concurrently with said merger. The trial will have 18 patients with hematological malignancies who are undergoing a haploidentical Bone Marrow Transplantation.
“This is an important milestone for Cellect and demonstrates the team’s professionalism and dedication for getting us to this occasion”
Dr. Shai Yarkoni, Chief Executive Officer
“This is an important milestone for Cellect and demonstrates the team’s professionalism and dedication for getting us to this occasion,” commented Dr. Shai Yarkoni, Chief Executive officer. “We look forward to working closely with EnCellX as its U.S. based team will work closely with Washington University to continue patient enrollment. This achievement, following the release of positive topline data from the Israeli ApoGraftTM trial, is timely as EnCellX is seeking to strengthen its balance sheet in the near term to fund continuing clinical development.”
